Collectively, the data from in vitro and in vivo studies using FUS, TDP-43, and C9orf72 models demonstrate that hUPF1 holds significant potential for treating the majority of patients with ALS and ...

Biotech, one of the Bay Area's most important industries, sprang up in five short decades. Here are the key moments to know ...

The Bay Area's biotech industry faces an uncertain future after 50 years. But industry leaders see a history of resilience ...

BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

The move comes as GSK faces pressure to replenish its pipeline, with some of its top-selling drugs nearing the end of their ...

The discovery of recombinant DNA proved that biology, not chemistry alone, could create new medicines like life-saving insulin.

So, the natural question for BRAIN Biotech (ETR:BNN) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Modern biotechnology began in 1973 when scientists used recombination to genetically engineer an antibiotic-resistant strain of Escherichia coli bacteria. This began a revolution in molecule ...